Solid growth momentum for the second year in a row Full-year revenue: €841.1 million, with growth of 9.0% on a like-for-like basis and at CERThis performance was achieved thanks to strong ...

Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device ...

Medicaid MCR is forecasted at 89.9% for 2025, with most rate increases already known. Medicare is expected to see a slightly elevated MCR above target due to utilization pressure and suboptimal recent ...

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.